| Website | colucid.com |
| Category | BioTech |
| Phone | 919-806-4304 |
| Employees |
| TOTAL | $7.5M |
| VENTURE FUNDING TOTAL | $7.5M |
| Venture Round, 8/11 Pappas Ventures Domain Associates Care Capital Pearl Street Venture Funds Triathlon Medical Venture Partners | $7.5M |
CoLucid Pharmaceuticals, Inc., a biotechnology company, focuses on therapies for central nervous system disorders. The company develops COL-144, a neurally acting anti-migraine agent, which is designed to treat migraine; and COL-204, a conjugated stigmine platform that produces novel chemical entities for therapy of sleep/wake disorders, chronic pain, Alzheimer’s disease, and psychiatric disorders. CoLucid Pharmaceuticals was founded in 2005 and is based in Research Triangle Park, North Carolina.
